HUP0401818A2 - Eljárás hepatitis vírusfertőzés kezelésére multifázisos interferon felszabadulású profillal - Google Patents

Eljárás hepatitis vírusfertőzés kezelésére multifázisos interferon felszabadulású profillal

Info

Publication number
HUP0401818A2
HUP0401818A2 HU0401818A HUP0401818A HUP0401818A2 HU P0401818 A2 HUP0401818 A2 HU P0401818A2 HU 0401818 A HU0401818 A HU 0401818A HU P0401818 A HUP0401818 A HU P0401818A HU P0401818 A2 HUP0401818 A2 HU P0401818A2
Authority
HU
Hungary
Prior art keywords
multiphasic
virus infection
antiviral agent
hepatitis virus
delivery profile
Prior art date
Application number
HU0401818A
Other languages
English (en)
Inventor
Gary Visor
Peter Vlasselaer
Original Assignee
Intermune, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune, Inc. filed Critical Intermune, Inc.
Publication of HUP0401818A2 publication Critical patent/HUP0401818A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

A találmány tárgya hepatitis vírusfertőzés kezelésére vonatkozik. Azeljárások általában egy antivirális szert tartalmazó készítményadagolását foglalják magukban olyan adagolási módban, amellyel aszérumban az antivirális szer multifázisos koncentrációprofiljavalósítható meg. Ez az adagolási mód kevésbé gyakori adagolásieseményt foglal magában, mint a napjainkban elérhetőhepatitisterápiák. A találmány szerinti eljárások alkalmazásával elértantivirális szer multifázisos szérumkoncentráció profilja kezdetigyors vírustiter-csökkenést; majd ezt követően a vírustiter továbbicsökkenését idézi elő, és így hosszan tartó vírusválasz alakul ki. Ó
HU0401818A 2001-10-05 2002-09-26 Eljárás hepatitis vírusfertőzés kezelésére multifázisos interferon felszabadulású profillal HUP0401818A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32774401P 2001-10-05 2001-10-05
PCT/US2002/030837 WO2003030923A1 (en) 2001-10-05 2002-09-26 Method of treating hepatitis virus infection with a multiphasic interferon delivery profile

Publications (1)

Publication Number Publication Date
HUP0401818A2 true HUP0401818A2 (hu) 2004-11-29

Family

ID=23277854

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401818A HUP0401818A2 (hu) 2001-10-05 2002-09-26 Eljárás hepatitis vírusfertőzés kezelésére multifázisos interferon felszabadulású profillal

Country Status (15)

Country Link
US (2) US20050063949A1 (hu)
EP (1) EP1450838A4 (hu)
JP (1) JP2005508943A (hu)
KR (1) KR20050030886A (hu)
CN (1) CN1738635A (hu)
AR (1) AR036728A1 (hu)
BR (1) BR0213103A (hu)
CA (1) CA2460690A1 (hu)
HU (1) HUP0401818A2 (hu)
IL (1) IL160965A0 (hu)
MX (1) MXPA04003238A (hu)
NO (1) NO20041814L (hu)
PL (1) PL369870A1 (hu)
WO (1) WO2003030923A1 (hu)
ZA (1) ZA200402236B (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002225870B2 (en) 2000-11-03 2006-09-21 Intarcia Therapeutics, Inc. Method for short-term and long-term drug dosimetry
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1561470A1 (en) * 2003-06-20 2005-08-10 Innogenetics N.V. HCV vaccines comprising the envelope-1 (E1) protein or the corresponding DNA and at least one antiviral agent
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
JP5323832B2 (ja) 2007-08-07 2013-10-23 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 酸性水溶液中にｇｄｆ−５を含むタンパク質製剤
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
WO2009120991A2 (en) * 2008-03-27 2009-10-01 Medtronic, Inc. Pharmacokinetic and pharmacodynamic tools to define patient specific therapeutic regimens
US20090246171A1 (en) * 2008-03-27 2009-10-01 Van Antwerp William P Automatic system for dose control in treating hepatitis c using infusion pumps
CA2720845A1 (en) 2008-04-14 2009-10-22 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered gdf-5 formulations
US9561214B2 (en) * 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
SI2462246T1 (en) 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Fast-setting and / or cessation of substantially unchanged delivery of the product
WO2011159930A2 (en) 2010-06-16 2011-12-22 Medtronic, Inc. Damping systems for stabilizing medications in drug delivery devices
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
CN103071147A (zh) * 2011-10-26 2013-05-01 麦德托尼克公司 干扰素-α向乙型肝炎感染的患者的连续皮下施用
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR20240042548A (ko) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6455051B1 (en) * 1997-10-13 2002-09-24 Otsuka Pharmaceutical Co., Ltd. Ameliorant for hepatitis C therapeutic effect and application thereof
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
US6245740B1 (en) * 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
AU2002225870B2 (en) * 2000-11-03 2006-09-21 Intarcia Therapeutics, Inc. Method for short-term and long-term drug dosimetry

Also Published As

Publication number Publication date
ZA200402236B (en) 2005-03-22
KR20050030886A (ko) 2005-03-31
JP2005508943A (ja) 2005-04-07
MXPA04003238A (es) 2004-07-08
WO2003030923A1 (en) 2003-04-17
EP1450838A4 (en) 2005-09-28
BR0213103A (pt) 2004-09-21
US20050063949A1 (en) 2005-03-24
CN1738635A (zh) 2006-02-22
AR036728A1 (es) 2004-09-29
CA2460690A1 (en) 2003-04-17
EP1450838A1 (en) 2004-09-01
NO20041814L (no) 2004-06-11
US20090196853A1 (en) 2009-08-06
PL369870A1 (en) 2005-05-02
IL160965A0 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
HUP0401818A2 (hu) Eljárás hepatitis vírusfertőzés kezelésére multifázisos interferon felszabadulású profillal
TW200509961A (en) Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
IL215891A (en) Hepatitis C Serine Protease Inhibitors, Pharmaceutical Compounds Containing Them, and Their Use in Preparing Drugs to Treat Hepatitis C Infections
MY141025A (en) Dose forms
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
JO2318B1 (en) Nucleoside derivatives used as DNA-based viral RNA inhibitors
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
TWI317735B (en) Methods and compositions for treating hepatitis c virus
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
IL184162A (en) Preparations containing irna materials, their pharmaceutical compositions and their use in the manufacture of drugs to lower the level of synthetic respiratory virus (rsv) protein, rsv mrna or @ rsv concentration @
DE60125797D1 (de) Impfstoffzusammesetzung
EE05442B1 (et) V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks
MXPA03006971A (es) Tratamiento del virus de hepatitis b.
HUP0105070A2 (hu) Hepatitis B vírus fertőzések megelőzésére és kezelésére szolgáló készlet
WO2005056051A3 (en) Hepatitis b vaccines and compositions
NO20032597L (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
AU5632701A (en) Pneumovirus ns proteins antagonising the interferon (ifn) response
HUP0302884A2 (hu) Módszer hepatocitába való gyógyszerbejuttatásra és flaviridae fertőzések kezelésére
AU2003298578A8 (en) Vaccines containing viruses involved in avian malabsorption syndrome and methods of administration therefor
WO2002087600A8 (de) Verwendung von phyllanthusbestandteilen zur behandlung oder prophylaxe von infekten durch hepatitis b-viren
WO2001077157A3 (en) Full-length gb virus c (hepatitis g virus) rna transcripts are infectious in primary cd4 positive t cells and methods of treating hiv
ATE468130T1 (de) Inhibitoren der kostimulation via ox40 und deren verwendung gegen eine von virusen induzierten immunpathologie
WO2004006843A3 (en) Combination therapies with l-fmau for the treatment of hepatitis b virus infection
DK1311279T3 (da) Behandling af hepatitis C med thymosin, interferon og ribavirin
WO2002078717A3 (en) Compositions and methods for reducing rna virus pathogenicity

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees